H
Harbour BioMed
Biotech & Life Sciences · Cambridge, United States · Founded 2016 · IPO 2020
Biopharmaceutical company developing fully human antibody therapeutics for oncology and immunology MoreLess
Harbour BioMed is a global biopharmaceutical company focused on the discovery, development and commercialisation of novel antibody therapeutics for oncology, immunology and other therapeutic areas. Its proprietary Harbour Mice platform generates fully human monoclonal antibodies in two formats - H2L2 and heavy chain only (HCAb) - while the HCAb-based immune cell engagers (HBICE) are designed to deliver tumour-killing effects beyond what traditional combination therapies achieve.
The company combines internal R&D with strategic global collaborations, co-discovery and co-development partnerships, and selective acquisitions. Its platform has been licensed to biopharma partners including BeiGene and Innovent Biologics for fully human monoclonal antibody drug discovery.
Harbour BioMed operates globally, with a presence in the United States, Europe and China, and listed on the Hong Kong Stock Exchange (HKEX: 02142) in December 2020. The company continues to advance a pipeline of novel antibody therapeutics powered by its fully human antibody discovery engine.
Keywords: biopharmaceutical, antibody therapeutics, oncology, immunology, Harbour Mice, monoclonal antibodies, HBICE, drug discovery, biotech, HKEX
Talent graph
Harbour BioMed's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Harbour BioMed has talent and traffic
team presence
across markets
Patent intelligence
$48M patent portfolio · 89 active families
Where Harbour BioMed concentrates vs peers
Each axis is a top-10 topic across Harbour BioMed and its closest peers. #1 = 100, #10 = 10, absent = 0.
Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.
Market sentiment
What the market is saying about Harbour BioMed
An AI-synthesized read of the highest-engagement posts about Harbour BioMed on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Harbour BioMed on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.